Royce & Associates’s GenMark Diagnostics, Inc GNMK Stock Holding History

Royce & Associates’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,000	Closed	-$177K	–	1207
2020 Q2	$177K	Sell	12,000 -19,100	-61%	-$194K	﹤0.01%	949
2020 Q1	$128K	Hold	31,100	–	–	﹤0.01%	957
2019 Q4	$150K	Hold	31,100	–	–	﹤0.01%	982
2019 Q3	$188K	Sell	31,100 -45,000	-59%	-$281K	﹤0.01%	981
2019 Q2	$494K	Hold	76,100	–	–	﹤0.01%	909
2019 Q1	$540K	Hold	76,100	–	–	﹤0.01%	918
2018 Q4	$370K	Sell	76,100 -12,600	-14%	-$65.6K	﹤0.01%	950
2018 Q3	$652K	Hold	88,700	–	–	﹤0.01%	962
2018 Q2	$566K	Sell	88,700 -14,700	-14%	-$97.2K	﹤0.01%	1010
2018 Q1	$562K	Buy	103,400 +37,500	+57%	+$186K	﹤0.01%	1040
2017 Q4	$275K	Buy	+65,900	New	+$397K	﹤0.01%	1076

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Royce & Associates's GNMK Position: Q3 2020 in Review

Royce & Associates sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2020, closing a stake of 12,000 shares — an estimated $177K sold.

Royce & Associates first reported a position in GNMK in Q4 2017 and held it in 11 quarters. The position peaked at $652K in Q3 2018. 163 funds tracked by Wall St. Rank hold GNMK as of Q3 2020.

Royce & Associates reported no remaining GenMark Diagnostics, Inc position as of Q3 2020 after selling out during the quarter.
Royce & Associates sold 12,000 GenMark Diagnostics, Inc shares in Q3 2020, an estimated $177K.
Royce & Associates first reported a position in GenMark Diagnostics, Inc in Q4 2017 and held it in 11 quarters.
Royce & Associates's GenMark Diagnostics, Inc position peaked at $652K in Q3 2018.
163 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.